ArticlePloS one2014
Cysteine peptidases as schistosomiasis vaccines with inbuilt adjuvanticity.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 62 citations in OpenAlex.
- Schistosoma japonicum cathepsin L1: A potential target for anti-schistosomiasis strategies.PLoS neglected tropical diseases · 2025Article
- Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review.PLoS neglected tropical diseases · 2025Article
- Schistosoma mansoni vaccine candidates identified by unbiased phage display screening in self-cured rhesus macaques.NPJ vaccines · 2024Article
- Chromosome-scale genome of the human blood fluke Schistosoma mekongi and its implications for public health.Infectious diseases of poverty · 2023Article
- Advances in new target molecules against schistosomiasis: A comprehensive discussion of physiological structure and nutrient intake.PLoS pathogens · 2023Review
- Molluscicidal and Larvicidal Potency ofPharmaceutics · 2023Article
- Increased hepatic interleukin-1, arachidonic acid, and reactive oxygen species mediate the protective potential of peptides shared by gut cysteine peptidases against Schistosoma mansoni infection in mice.PLoS neglected tropical diseases · 2023Article
- A low dose adenovirus vectored vaccine expressing Schistosoma mansoni Cathepsin B protects from intestinal schistosomiasis in mice.EBioMedicine · 2022Article
- Screening of a Library of Recombinant Schistosoma mansoni Proteins With Sera From Murine and Human Controlled Infections Identifies Early Serological Markers.The Journal of infectious diseases · 2022Article
- Comparative transcriptome profiles of Schistosoma japonicum larval stages: Implications for parasite biology and host invasion.PLoS neglected tropical diseases · 2022Article
- A comprehensive and critical overview of schistosomiasis vaccine candidates.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Review
- Promising Technologies in the Field of Helminth Vaccines.Frontiers in immunology · 2021Review
- Article
- Current status and future prospects of protein vaccine candidates againstParasite epidemiology and control · 2020Review
- Review
- Adjuvant-free schistosome cathepsin L3 is an efficacious schistosomiasis vaccine-comment on Huang et al.: Characteristics and function of cathepsin L3 from Schistosoma japonicum.Parasitology research · 2020Article
- Arachidonic Acid Is a Safe and Efficacious Schistosomicide, and an Endoschistosomicide in Natural and Experimental Infections, and Cysteine Peptidase Vaccinated Hosts.Frontiers in immunology · 2020Review
- Vaccination against the digestive enzyme Cathepsin B using a YS1646 Salmonella enterica Typhimurium vector provides almost complete protection against Schistosoma mansoni challenge in a mouse model.PLoS neglected tropical diseases · 2019Article
- Role of T lymphocytes and papain enzymatic activity in the protection induced by the cysteine protease againstJournal of advanced research · 2019Article
- A secreted schistosome cathepsin B1 cysteine protease and acute schistosome infection induce a transient T helper 17 response.PLoS neglected tropical diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
Abstract
Schistosomiasis is caused by several worm species of the genus Schistosoma and afflicts up to 600 million people in 74 tropical and sub-tropical countries in the developing world. Present disease control depends on treatment with the only available drug praziquantel. No vaccine exists despite the intense search for molecular candidates and adjuvant formulations over the last three decades. Cysteine peptidases such as papain and Der p 1 are well known environmental allergens that sensitize the immune system driving potent Th2-responses. Recently, we showed that the administration of active papain to mice induced significant protection (P<0.02, 50%) against an experimental challenge infection with Schistosoma mansoni. Since schistosomes express and secrete papain-like cysteine peptidases we reasoned that these could be employed as vaccines with inbuilt adjuvanticity to protect against these parasites. Here we demonstrate that sub-cutaneous injection of functionally active S. mansoni cathepsin B1 (SmCB1), or a cathepsin L from a related parasite Fasciola hepatica (FhCL1), elicits highly significant (P<0.0001) protection (up to 73%) against an experimental challenge worm infection. Protection and reduction in worm egg burden were further increased (up to 83%) when the cysteine peptidases were combined with other S. mansoni vaccine candidates, glyceraldehyde 3-phosphate dehydrogenase (SG3PDH) and peroxiredoxin (PRX-MAP), without the need to add chemical adjuvants. These studies demonstrate the capacity of helminth cysteine peptidases to behave simultaneously as immunogens and adjuvants, and offer an innovative approach towards developing schistosomiasis vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.